

**C. Agnostini** is a member of the Italian INTERMUNE Advisory Board on pirfenidone and IPF; he received an educational grant from Boehringer Ingelheim; and travel to the ATS congress was funded by Boehringer Ingelheim.

**R.C. Chambers** currently receives research funding for collaborative studies on lung fibrosis from GlaxoSmithKline.

**V. Cottin** has received fees for speaking or consulting from Actelion, Boehringer Ingelheim, Centocor, Intermune, Lilly and Pfizer and has participated as an investigator to clinical trials sponsored by Actelion, Boehringer Ingelheim and Intermune, and as member of steering committee to a clinical trial sponsored by Boehringer Ingelheim.

**H. Parfrey** has received fees for consulting from Intermune.

**A. Wells** has received fees for advisory board membership from InterMune and consultancy from Actelion, AstraZeneca, Boehringer Ingelheim, Centercor, Encysive, Genentech, Gilead, Intermune, MedImmune and Novartis. He has also received payment for lectures from Intermune, Actelion and Boehringer Ingelheim, and fees for travel from Intermune and Boehringer Ingelheim.